959 related articles for article (PubMed ID: 10693867)
1. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
2. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
3. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint.
Cawston TE; Curry VA; Summers CA; Clark IM; Riley GP; Life PF; Spaull JR; Goldring MB; Koshy PJ; Rowan AD; Shingleton WD
Arthritis Rheum; 1998 Oct; 41(10):1760-71. PubMed ID: 9778217
[TBL] [Abstract][Full Text] [Related]
4. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
[TBL] [Abstract][Full Text] [Related]
5. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
[TBL] [Abstract][Full Text] [Related]
6. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
[TBL] [Abstract][Full Text] [Related]
7. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis.
Lohmander LS; Ionescu M; Jugessur H; Poole AR
Arthritis Rheum; 1999 Mar; 42(3):534-44. PubMed ID: 10088777
[TBL] [Abstract][Full Text] [Related]
8. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice.
de Hooge AS; van de Loo FA; Bennink MB; Arntz OJ; Fiselier TJ; Franssen MJ; Joosten LA; Van Lent PL; Richards CD; van den Berg WB
Arthritis Rheum; 2003 Jun; 48(6):1750-61. PubMed ID: 12794844
[TBL] [Abstract][Full Text] [Related]
9. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.
Kobayashi M; Squires GR; Mousa A; Tanzer M; Zukor DJ; Antoniou J; Feige U; Poole AR
Arthritis Rheum; 2005 Jan; 52(1):128-35. PubMed ID: 15641080
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.
Hui W; Rowan AD; Richards CD; Cawston TE
Arthritis Rheum; 2003 Dec; 48(12):3404-18. PubMed ID: 14673992
[TBL] [Abstract][Full Text] [Related]
11. [Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis].
Neidel J; Schulze M; Sova L; Lindschau J
Z Orthop Ihre Grenzgeb; 1996; 134(4):381-5. PubMed ID: 8928570
[TBL] [Abstract][Full Text] [Related]
12. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine.
Taniguchi N; Kawahara K; Yone K; Hashiguchi T; Yamakuchi M; Goto M; Inoue K; Yamada S; Ijiri K; Matsunaga S; Nakajima T; Komiya S; Maruyama I
Arthritis Rheum; 2003 Apr; 48(4):971-81. PubMed ID: 12687539
[TBL] [Abstract][Full Text] [Related]
13. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.
Ishiguro N; Ito T; Ito H; Iwata H; Jugessur H; Ionescu M; Poole AR
Arthritis Rheum; 1999 Jan; 42(1):129-36. PubMed ID: 9920023
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid synovial fluid contains bioactive leukemia inhibitory factor with cartilage degrading activity--another target for chondroprotective intervention.
Bell MC; Carroll GJ
J Rheumatol; 2000 Feb; 27(2):332-8. PubMed ID: 10685793
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase.
Blom AB; Radstake TR; Holthuysen AE; Slöetjes AW; Pesman GJ; Sweep FG; van de Loo FA; Joosten LA; Barrera P; van Lent PL; van den Berg WB
Arthritis Rheum; 2003 Apr; 48(4):1002-14. PubMed ID: 12687542
[TBL] [Abstract][Full Text] [Related]
16. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
18. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis.
Poole AR; Ionescu M; Swan A; Dieppe PA
J Clin Invest; 1994 Jul; 94(1):25-33. PubMed ID: 7518830
[TBL] [Abstract][Full Text] [Related]
19. Galectin 3 and its binding protein in rheumatoid arthritis.
Ohshima S; Kuchen S; Seemayer CA; Kyburz D; Hirt A; Klinzing S; Michel BA; Gay RE; Liu FT; Gay S; Neidhart M
Arthritis Rheum; 2003 Oct; 48(10):2788-95. PubMed ID: 14558084
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
Danning CL; Illei GG; Hitchon C; Greer MR; Boumpas DT; McInnes IB
Arthritis Rheum; 2000 Jun; 43(6):1244-56. PubMed ID: 10857783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
